The National Association of Specialty Pharmacy (NASP) filed an amicus brief on March 2, 2020, in support of the case going before the Supreme Court on April 27, 2020 to decide on states’ rights to regulate pharmacy benefit managers (PBMs). The case Rutledge v. the Pharmaceutical Care Management Association (PCMA) will determine whether states can regulate pharmacy reimbursement, overseeing PBM practices, or whether the Employee Retirement Income Security Act (ERISA) preempts states from regulating such practices.
NASP’s Comments on the Office of Inspector General (OIG) Department of Health and Human Services (HHS) proposed regulation, “Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees” [84 Fed. Reg. No. 25, February 6, 2019; OIG-0936-P; RIN 0936-AA08].
NASP’s Comments on Centers for Medicare and Medicaid Services’ (CMS) proposed regulation, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses” [83 Fed. Reg. No. 231, November 30, 2018; CMS-4180-P; RIN 0938-AT92).
Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program